



MEDIGUS
Corporate Presentation

May 2022

NASDAQ: MDGS

Forward Looking Statements

This presentation may contain statements about Medigus Ltd. and its subsidiaries (the “Company”) that are “Forward-Looking Statements,” which are based upon the current estimates, assumptions and expectations of the Company’s management and its knowledge of the relevant market, including but not limited to statements regarding anticipated development and commercialization activities and market opportunities. The Company has tried, where possible, to identify such information and statements by using words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These forward-looking statements represent the Company’s expectations or beliefs concerning future events, and it is possible that the events described in this presentation will not be achieved, due to, inter alia, the spread of COVID-19 as well as the restriction deriving therefrom. By their nature, Forward-Looking Statements involve known and unknown risks, uncertainties and other factors which may cause future results of the Company’s activity to differ significantly from the content and implications of such statements. Other risk factors affecting the company are discussed in detail in the Company’s filings with the Securities and Exchange Commission. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements, whether as a result of new information, future developments or otherwise. Neither the Company nor its shareholders, officers and employees, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of Company securities. Nothing in this presentation should be deemed to be medical or other advice of any kind.



MEDIGUS

NASDAQ: MDGS

Investment Highlights

Medigus Ltd. is a technology-based company engaged in advancing innovative solutions for large-scale market applications.

Our Company is focused on capturing early stage companies or technology opportunities and turning them in multi million dollar value assets in minimum time and resources.



Our Strengths

Designed for maximum flexibility, allowing the Company to develop, commercialize, and support a broad array of new technologies with high growth potential.

Focused Strategy on High-End Technology

Our Company is focused on partnering and cooperating with start-up / early stage companies from broad array of technologies.



Fast and Agile

Highly Experienced Management

Management and BOD with deep and extensive experience in structuring deals.

Highly innovative technologies along side growing revenue stream



The Medigus Magic

Step 1

partnering with early stage, high-end technology companies (usually from our local Israeli start-up hub)

Step 2

Leveraging our management extensive expertise and networking. Expose it to new markets, experts and end users

Step 3

Breeding a conceptual technology into a real, existing company. Company is trading in multi million valuation, bringing value to its shareholders and Medigus'

We've done it many times before with various technologies. We will continue doing it further.

This is what makes us unique

We are Medigus.

How We Do It?

ScoutCam Case Study

- Scoutcam's IP was fully owned by Medigus
- In December 2019 - Medigus completed a deal to merge Scoutcam to a listed company on OTC market - becoming a public company
- With the help of Medigus, Scoutcam raised \$3.3 million along with the OTC listing
- In February 2021, Leading Life Science and Pharmaceutical Entrepreneur Mori Arkin invested \$2 million in ScoutCam and joined its Board of Directors. Mr Arkin founded Arkin Holdings, which owns a healthcare portfolio of \$1 billion through four investment arms, with holdings in some 20 Israeli companies developing pharmaceutical drugs and medical equipment, such as UroGen Pharma (Nasdaq: URGN), Keros Therapeutics (Nasdaq: KROS) and Novolog (TASE: NVLG).
- In March 2021 Medigus facilitated a private placement of \$20 million from institutional investors for ScoutCam
- ScoutCam's current valuation ~\$57 million, Medigus holds 27.02% (OTCQB:SCTC)

Financial Highlights



Record Revenue



\$10.1M

Up 1,805% over 2020

Shareholders' Equity



\$49M

Improved 114% in 2021, up from
\$23 million at year-end 2020

Net Income



\$4M

Up from a net loss of
\$6.9 million in 2020

Cash & Cash Equivalents



~\$24M

Cash & cash equivalents as of 12/31/21,
up from \$22.4 million at year-end 2020

Gross Margin



47%

And 40% net margin

Business Highlights



- Revoltz completed prototype manufacturing of its micro-mobility vehicle
- Charging Robotics signed a definitive agreement with Automax Motors Ltd. for exclusive distribution of its wireless robotic charging pad in Israel and Greece
- Jeffs Brands filed for IPO
- Eventer filed for IPO
- Polyrizon began in-vitro tests of its innovative product candidate for protection against the Omicron variant
- Gix reported 2021 revenues of \$45.2 million, up 19.1%



2022 Looking Forward



- High double digit revenue growth
- Consolidation of 100% of GIX's revenue
- GIX 1Q-22 revenue: \$20 million: EBIDTA \$750K
- Two IPOs: Eventer and Jeff's Brands
- Reverse Merger: Charging Robotics
- \$3 million share buyback program



JEFFS BRANDS



Cap Table(ADS basis)



Shareholders	Share capital on as diluted basis	Fully diluted Ownership
Public	24,591,470	80.46%
Warrants	4,297,424	14.06%
ESOP - Management	1,212,500	3.97%
ESOP - Employees and Consultants	461,350	1.51%
Total	30,562,744	100%

The Main Market Segments We Invest In

Online Technologies



Rev: \$45M, 38.03%, TAM: \$345B

JEFFS BRANDS

Rev: \$6.5M, 50.03%, TAM: \$356B



NOT Anything™ in the Digital World

TAM: \$10.7B



Rev: \$1.2M, 47.69%, TAM: \$15.7B

EV & Micro Mobility



100%, TAM: \$827M



19.9%, TAM: \$108B



40.35%

Healthcare



27.02%, TAM: \$16B



37.03%, TAM: \$19.5B



The Main Market Segments We're Operating at

Online Technologies



Rev: \$45M, 38.03%, TAM: \$345B

JEFFS BRANDS

Rev: \$6.5M, 50.03%, TAM: \$356B



NFT Anything™ in The Digital World

TAM: \$10.7B



Rev: \$1.2M, 47.69%, TAM: \$15.7B

EV & Micro Mobility



100%, TAM: \$827M



19.9%, TAM: \$108B



40.35%

Healthcare



27.02%, TAM: \$16B



37.03%, TAM: \$19.5B



gix

TASE: GIX.TA





Performance-Based-Marketing

- Gix Group (TASE:GIX) is a global leader in MarTech (Marketing Technology) solutions, mainly for online performance-based-marketing, that maximizes exposure, increases impact and drives profits from target audiences, operate through its subsidiary Linkury
- Gix Internet's subsidiary, Gix Media completed the acquisition of 70% of Cortex Group, an innovative media-tech company that has developed expertise in turning original content into a profit center through user traffic acquisition

Facts & Figures

38.03%

Medigus' holdings as of
May 12, 2022

~\$8.7M

Shareholders' equity as
of December 31, 2021

12M

Worldwide
users

100+

Products


45\$~M

Revenues in 2021



New Attractive Structure

- In March 2021, Gix's BOD established a committee to identify new opportunities and activities to merge with Gix. If a new activity is found and leads to a binding agreement and a merger, Gix Internet will examine the possibility of taking Gix Media public and/or distributing its shares as a dividend to Gix's shareholders



JEFFS BRANDS

e- Commerce

Market Gap and Opportunity

E-Commerce market had a break out year in 2020, inter alia, due to the Covid-19 pandemic accelerating on-line shopping and spending, resulting in increased revenues on a global level

Amazon is the largest retailer now in the US, suppressing Walmart.

Amazon Marketplace

\$4.5 trillion

projected e-commerce market value (2020)*

3 MM

active stores*(2019)

2 B

buyers (2019)*

Amazon owns**

45%

of U.S. e-commerce

Market

150.6MM

mobile users (Sep 2019)**

2.5 MM

sellers**

4000

items sold per minute**

*Source: 2020 ecommerce statistics

** Source: 10 Amazon Statistics You Need to Know in 2020

Jeff's Brands: Data-Driven E-commerce

- Jeff's Brands Ltd., and its subsidiaries Smart Repair Pro, Purex and Top Rank, is a fast-growing consumer products goods (CPG) company, operating primarily on Amazon.com
- Jeff's Brands leverage proprietary artificial intelligence (AI) and machine learning to analyze sales data and patterns within the multi-billion-dollar Amazon marketplace to identify stores, niches and products with demonstrated growth potential to maximize sales within their Fulfillment By Amazon (FBA) shops.
- Smart Repair has approved for operation in Germany, UK, France, Spain, Italy and Australia in short order

Facts & Figures

50.03%

Medigus' holdings

6

Brands

\$6.5M

Revenues in 2021



Success Story #1

Knife Sharpening Stone



+11

New Product
Development

**Inventory
Build-Up**

Word Wide
Logistic &
Production
relations

May 2018

Date of Acquisition

April 2019

REVENUE \$0.5M (12-months Pre-Acquisition)

April 2019

PROFIT \$0.2M

May 2019

REVENUE \$1.1M (12-months Post-Acquisition)

May 2020

PROFIT \$0.4M



NFT Anything™ In The Digital World

Non- Fungible Token

What's the Market Gap / Opportunity?

The first digital “Mona Lisa”

In the physical world, even if many forgeries of the Mona Lisa exist, only the authenticated original retains the true value.

The same concept applies for a digital collectible. The copying/duplication of the actual work does not necessarily have a negative impact on the value of the original. If anything, the additional visibility that the copying/duplication brings will go toward increasing its value.

People can go on to right-click and save the file, but it won't mean they truly own the item.

The Forever Rose - Kevin Abosch, digital art, work sold for \$1 million in cryptocurrency.

of collectibles is digital | TechCrunch 31.03.2020



The Forever Rose

Kevin Abosch, digital art, work sold
for \$1 million in cryptocurrency



NFT- Safee and Joint Venture

Medigus entered NFT Space with a first investment in Blockchain company Safee.

Safee's social network allows creators and collectors to easily create, own, engage, control and trade digital goods. Safee's mission is to expand the reach of NFTs to mass market buyers and creators, digital artists, illustrators, photographers, musicians, regular consumer digital content creators and more.

\$5M Joint Venture

Medigus signed a non-binding MOU with Safee, for a **joint venture** to trade and monetize NFTs and other digital assets.

The JV will use Safee's knowledge and platform to identify opportunities in the NFT field, and to buy, hold and monetize NFTs. Medigus will help fund the collaborative enterprise with a loan of up to \$5 million for the purchase of NFTs and other digital assets





eventer

Online Event Platform

Eventer Overview

Eventer is a smart ticketing platform, enabling producers and venues to create events, manage ticket operations and boost ticket sales, all in one efficient and cost-effective platform.

Eventer and Screenz' Cross Media Ltd.

Eventer entered the multi-billion virtual conference market by signing an exclusive licensing agreement to adopt Screenz Cross Media Ltd. technology for virtual conferences.

Screenz is a virtual entertainment and events technology company whose customer base includes Reliance Industries (a Fortune 500 company and the largest private-sector corporation in India), Fox, ABC, Disney, Univision and Viacom.



Facts & Figures

47.69%

Medigus' holdings

\$2.4M



Tickets sold 2018-2021

\$600K

In commissions

1.7M

Producers & artists



The Main Market Segments We're Operating at

Online Technologies



Rev: \$45M, 34.58%, TAM: \$345B

JEFFS BRANDS

Rev: \$6.5M, 50.03%, TAM: \$356B



NFT Anything™ in The Digital World

TAM: \$10.7B



Rev: \$1.2M, 47.69%, TAM: \$15.7B

EV & Micro Mobility



100%, TAM: \$827M



19.9%, TAM: \$108B



40%

Healthcare



27.02%, TAM: \$16B



37.03%, TAM: \$19.5B





ParaZero Safety Solutions Enable Global Drone Deliveries at Scale

- ParaZero SafeAir™ system applies real-time data analytics to identify and mitigate flight risks autonomously and increase safety for bystanders while protecting the loss of expensive drones, equipment, and payloads
- ParaZero's safety technology contains a portfolio of ASTM F3322-18 compliant parachute recovery systems for leading enterprise drone platforms, including the DJI Mavic 2, Phantom 4, Matrice 200, Matrice 300, and the AIROBOTICS Optimus drone, among a number of others in development
- Achieving certification for the ASTM F3322-18 standard requires 45 successful aerial parachute deployments, across a number of failure scenarios, in the presence of an approved third-party testing agency



Effective and reliable
in all failure scenarios



Extremely effective
ground risk mitigation



Very low minimum
safe altitude





Wireless Charging System



What's the Market Gap / Opportunity?

- Number of electric cars sold is expected to grow to 26.9M by year 2030
- The International Energy Agency forecasts that as many as 30 million public chargers would be needed to serve regular passenger vehicles – a number 50 times in excess of today's
- The market currently relies on one solution only- cable charging, the industry is in search for new cutting edge technologies to close the "Energetic Gap"

EVs Units Sold [M]

Source: IEA report, MarketandMarkets, Capgemini Invent, 2019



Our Solution:

Autonomous Charging System

- Charging Robotics (Medigus' wholly owned subsidiary) is out to change the way Electric Vehicles are charged
- Charging Robotics develops a robotic platform for charging vehicles in a wireless and automatic manner
- No more plugs, No more cables, No more searching for a parking spot with a charger. At the heart of the technology is a wireless power transfer module that uses resonance coils to transfer energy wirelessly from the robot to the vehicle.

Facts & Figures

100%

Medigus' holdings

93%

Charging efficiency of

3mm

Robot Accuracy





Our Solution: Autonomous Charging System

- The robotic platform is small enough to fit under the vehicle, it automatically positions itself for maximum efficiency charging and returns to its docking station at the end of the charging operation.
- In July 2021, Charging Robotics has concluded a proof of concept, successfully demonstrating the capabilities of its electric vehicle wireless charging robot.



REVOLTZ

EV and Wireless Charging Joint Venture



What's the Market Gap / Opportunity?

The last mile problem/ challenge:

- Last mile is a term used in logistics planning to describe the last leg of a journey
- This leg is comprising the movement of goods from a transportation hub to a final destination
- The last mile describes the difficult last part in the transportation of packages from hubs to final destinations



EV Micro-Mobility Vehicles

Revoltz is a joint venture between Medigus, through its wholly owned subsidiary, Charging Robotics Ltd., and Revoltz 'founders, a privately held company that designs and develops electric micro-mobility vehicles

Revoltz 'focus is developing EVs to meet the demands of commercial users and mission-specific designs, including full workday single charge, heavy-duty and rigid operations, Hop-on-Hop-off modes, off-road travel and a low cost of operation

Revoltz 'Model One- micromobility vehicle for last mile and food delivery:

- > first of it's kind cargo e-scooter
- > full day of work in one charge
- > robust and compact design
- > perfect last mile delivery
- > low operational costs



The Main Market Segments We're Operating at

Online Technologies



Rev: \$45M, 38.03%, TAM: \$345B

JEFFS BRANDS

Rev: \$6.5M, 50.03%, TAM: \$356B



NFT Anything™ in The Digital World

TAM: \$10.7B



Rev: \$1.2M, 47.69%, TAM: \$15.7B

EV & Micro Mobility



100%, TAM: \$827M



19.9%, TAM: \$108B



40.35%

Healthcare



27.02%, TAM: \$16B



37.03%, TAM: \$19.5B





Scoutcam
micro imaging technologies

OTCQB: SCTC

World's Smallest Cameras

As cameras become smaller and more accessible, the incorporation of innovative visualization technologies has increased across industries.



Facts & Figures

27.02%

Medigus' holdings as of May 11, 2022

2019

Scoutcam was founded operates state-of-the-art production facilities

7/8

ISO cleanrooms

1

Micro accuracy testing capabilities



Proprietary Technologies

All-inclusive, in-house technology

Components

- Micro CMOS Sensors
- Optics Design
- Video Processors

Additions

- Illumination
- Long Lightweight Cables
- Ultrasound Option

Integrations

- Endoscopes & Borescopes
- Task Specific Tools
- High Resistant Options





Polyrizon

Developing Innovative Intranasal
Products



What's the Market Gap / Opportunity?

- Nasal Viral Infections include corona virus, Influenza and other common cold infections
- Allergic Rhinitis is caused by airborne pollen, spores and dust
- Vaccines provides narrow protection against specific targets
- COVID-19 pandemic is also a driving force for this market creating a global recognition and need for prevention and not just treatment solutions
- Global influenza treatment (all types) market will reach \$1,371 billion by 2030, growing by 3.8% annually over 2020-2030
- Driven by rising incidences of influenza, growing awareness and need for new drugs and treatment across the globe





Protecting Against Biological Threats

A clinical development biotech company specializing in the development of innovative nasal gels to provide preventative treatment against a wide range of biological assaults, such as viruses, including COVID-19 and influenza, as well as allergens and other airborne pathogens.


Polyrizon's proprietary Capture and Contain™ (C&C) hydrogel platform, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and forms a thin protective shield containment barrier in the nasal cavity to prevent infection.

Prof of concept:

Recent pre-clinical studies by Polyrizon demonstrated the impact of the C&C product line that was capable to provide a barrier against allergens and a variety of different respiratory viruses such as cold, flu and COVID-19




Not Protected



- Viruses reach nasal epithelia
- Result in viral infection

Protected by C&C™



- Preventative treatment
- Protection against broad spectrum of biological threats
- Nasal spray topical administration – no injections
- Safe and Easy to use



 **MUSE** SYSTEM

Medigus Ultrasonic Surgical Endostapler



MUSE™ System

Comprehensive endoscopic, FDA approved, device that incorporates the latest technological advancements to deliver a more patient-friendly option for Transoral Fundoplication (TF) for the treatment of gastroesophageal reflux disease (GERD)

Dozens of patents worldwide

\$3 million Licensing and Sales Agreement with Shanghai Golden Grand-Medical Instruments Ltd. for exclusive license in China, Hong Kong, Taiwan and Macao.

Available via out-licensing agreements - working on new partners through similar MUSE™ system licensing and sale agreements in additional territories worldwide.





Why MEDIGUS

- Focused Strategy on High-End Technology
- Solid financial structure with attractive business model - no debt and more than \$24 million in cash and equivalents on a consolidated basis
- High capabilities in identify opportunities
- The ability to act fast, structure deals and execute them
- Proven success in turning an IP / innovative technologies to valuable assets
- In depth involvement at the company's projects, providing them with great resources and vast management experience





MEDIGUS

Thank you

NASDAQ: MDGS

www.medigus.com

 @Medigus3

www.linkedin.com/company/medigus/